Alkermes plc (NASDAQ:ALKS) reported positive interim results from its ongoing long-term extension (LTE) study of investigational oral therapy alixorexton, showing sustained improvements in wakefulness, daytime sleepiness, cognition, and fatigue in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).
Long-Term Data Show Durable Clinical Benefits
The interim analysis included participants who completed the Phase 2 Vibrance-1 (NT1) and Vibrance-2 (NT2) studies before enrolling in the open-label LTE.
The analysis included safety data through May 12, 2026, and efficacy assessments at week 24 of the extension study.
Read Next
